These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26244699)

  • 21. The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor.
    Bonaventure J; Horne WC; Baron R
    FEBS J; 2007 Jun; 274(12):3078-93. PubMed ID: 17509076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and initial characterization of FGFR3 transmembrane domain: consequences of sequence modifications.
    Iwamoto T; You M; Li E; Spangler J; Tomich JM; Hristova K
    Biochim Biophys Acta; 2005 Mar; 1668(2):240-7. PubMed ID: 15737335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene.
    Tavormina PL; Bellus GA; Webster MK; Bamshad MJ; Fraley AE; McIntosh I; Szabo J; Jiang W; Jabs EW; Wilcox WR; Wasmuth JJ; Donoghue DJ; Thompson LM; Francomano CA
    Am J Hum Genet; 1999 Mar; 64(3):722-31. PubMed ID: 10053006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans.
    Vajo Z; Francomano CA; Wilkin DJ
    Endocr Rev; 2000 Feb; 21(1):23-39. PubMed ID: 10696568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mild achondroplasia/hypochondroplasia with acanthosis nigricans, normal development, and a p.Ser348Cys FGFR3 mutation.
    Couser NL; Pande CK; Turcott CM; Spector EB; Aylsworth AS; Powell CM
    Am J Med Genet A; 2017 Apr; 173(4):1097-1101. PubMed ID: 28181399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of dimerization efficiency of transmembrane domains in activation of fibroblast growth factor receptor 3.
    Volynsky PE; Polyansky AA; Fakhrutdinova GN; Bocharov EV; Efremov RG
    J Am Chem Soc; 2013 Jun; 135(22):8105-8. PubMed ID: 23679838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crouzon syndrome with acanthosis nigricans and prominent diffuse hyperpigmentation associated with gain-of-function A391E mutation in FGFR3 gene.
    Kariya H; Nakano H; Ishii N; Kaimi Y; Imai K; Nakanishi Y; Kunihiro N; Fukai K
    J Dermatol; 2020 Dec; 47(12):e451-e452. PubMed ID: 32860240
    [No Abstract]   [Full Text] [Related]  

  • 28. Measuring the energetics of membrane protein dimerization in mammalian membranes.
    Chen L; Novicky L; Merzlyakov M; Hristov T; Hristova K
    J Am Chem Soc; 2010 Mar; 132(10):3628-35. PubMed ID: 20158179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
    Adar R; Monsonego-Ornan E; David P; Yayon A
    J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A recurrent mutation, ala391glu, in the transmembrane region of FGFR3 causes Crouzon syndrome and acanthosis nigricans.
    Wilkes D; Rutland P; Pulleyn LJ; Reardon W; Moss C; Ellis JP; Winter RM; Malcolm S
    J Med Genet; 1996 Sep; 33(9):744-8. PubMed ID: 8880573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term survival in typical thanatophoric dysplasia type 1.
    Baker KM; Olson DS; Harding CO; Pauli RM
    Am J Med Genet; 1997 Jun; 70(4):427-36. PubMed ID: 9182787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.
    Webster MK; D'Avis PY; Robertson SC; Donoghue DJ
    Mol Cell Biol; 1996 Aug; 16(8):4081-7. PubMed ID: 8754806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice.
    Iwata T; Li CL; Deng CX; Francomano CA
    Hum Mol Genet; 2001 Jun; 10(12):1255-64. PubMed ID: 11406607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum.
    Lievens PM; Liboi E
    J Biol Chem; 2003 May; 278(19):17344-9. PubMed ID: 12624096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenic Cysteine Removal Mutations in FGFR Extracellular Domains Stabilize Receptor Dimers and Perturb the TM Dimer Structure.
    Sarabipour S; Hristova K
    J Mol Biol; 2016 Oct; 428(20):3903-3910. PubMed ID: 27596331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary and secondary dimer interfaces of the fibroblast growth factor receptor 3 transmembrane domain: characterization via multiscale molecular dynamics simulations.
    Reddy T; Manrique S; Buyan A; Hall BA; Chetwynd A; Sansom MS
    Biochemistry; 2014 Jan; 53(2):323-32. PubMed ID: 24397339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.
    Jin M; Yu Y; Qi H; Xie Y; Su N; Wang X; Tan Q; Luo F; Zhu Y; Wang Q; Du X; Xian CJ; Liu P; Huang H; Shen Y; Deng CX; Chen D; Chen L
    Hum Mol Genet; 2012 Dec; 21(26):5443-55. PubMed ID: 23014564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia.
    Hyland VJ; Robertson SP; Flanagan S; Savarirayan R; Roscioli T; Masel J; Hayes M; Glass IA
    Am J Med Genet A; 2003 Jul; 120A(2):157-68. PubMed ID: 12833394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The A391E mutation enhances FGFR3 activation in the absence of ligand.
    Chen F; Degnin C; Laederich M; Horton WA; Hristova K
    Biochim Biophys Acta; 2011 Aug; 1808(8):2045-50. PubMed ID: 21536014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subtle radiographic findings of achondroplasia in patients with Crouzon syndrome with acanthosis nigricans due to an Ala391Glu substitution in FGFR3.
    Schweitzer DN; Graham JM; Lachman RS; Jabs EW; Okajima K; Przylepa KA; Shanske A; Chen K; Neidich JA; Wilcox WR
    Am J Med Genet; 2001 Jan; 98(1):75-91. PubMed ID: 11426459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.